Pozanicline
Alternative Names: A-87089.0; ABT-089Latest Information Update: 22 Jan 2013
At a glance
- Originator Abbott Laboratories
- Class Neuroprotectants; Nootropics; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Nicotinic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Anxiety disorders; Attention-deficit hyperactivity disorder; Schizophrenia
Most Recent Events
- 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
- 21 Oct 2009 Pharmacodynamics data from a preclinical study in ADHD presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
- 19 Nov 2008 Pharmacodynamics data from preclinical studies in ADHD and Alzheimer's disease and Cognition Disorders presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008) ,,,